| CHD |
Report |
Adj. EPS (Q2 2026) |
BEAT |
pred ~$0.91 vs. cons $0.894 |
MEDIUM |
| CHD |
Report |
Organic Sales Growth (Q2 2026) |
BEAT |
pred ~3.5% vs. cons 3.25% |
MEDIUM |
| CHD |
Report |
Net Sales (Q2 2026) |
IN-LINE |
pred ~$1,510M vs. cons $1,503M |
MEDIUM |
| CHD |
Guide |
Adj. EPS - Q3 2026 (Q3 2026) |
LOWER |
guide ~$0.87-0.89 vs. cons $0.893 |
MEDIUM |
| CHD |
Guide |
Adj. EPS - FY 2026 (FY 2026) |
LOWER |
reiterate $3.70-$3.80 vs. cons $3.753 (implicit H2 cut) |
MEDIUM |
| CHD |
Guide |
Organic Growth - FY 2026 (FY 2026) |
UNCHANGED |
reiterate 3-4% vs. cons 3.77% |
HIGH |
| CHD |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.0% |
— |
MEDIUM |
| CHD |
Return |
5-day cumulative residual |
-1.5% (STABILIZE) |
STABILIZE - organic beat floors the stock; Q3 guide below cons trims H2 estimates modestly; no further catalyst to drive sustained selling |
MEDIUM |